Niki BioSolutions Flags Going Concern, Weighs Financing After Post-Merger Losses
NIKI sits 43% above its 52-week low of $6 on light trading volume (0.4× avg).
Summary
Niki BioSolutions disclosed a going concern warning in its first post-merger financials, citing substantial doubt about its ability to continue over the next year. H1 net loss widened to $1.60 per share, with operating expenses rising sharply on higher R&D, G&A, and legal costs. The company is now weighing financing options to shore up liquidity. This follows the 8-K filed today and the July 13D showing a 51.56% insider stake. With a market cap under $7 million, the financing need is acute and could be highly dilutive. Watch for any announced capital raise terms.
At the time of this announcement, NIKI was trading at $8.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $6.00 to $44.70. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.